Non-HDL cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: The EPIC-Norfolk prospective population study

European Journal of Clinical Investigation

Volumn 43, Issue 10, 2013, Pages 1009-1015

  Sondermeijer, Brigitte M ^a   Rana, Jamal S ^b   Arsenault, Benoit J ^a   Shah, Prediman K ^c   Kastelein, John J P ^a   Wareham, Nicholas J ^d   Matthijs Boekholdt, S ^a   Khaw, Kay Tee ^d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Kaiser Permanente Northern California ^*  (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Apolipoprotein B; Coronary heart disease; Low density lipoprotein cholesterol; Non high density lipoprotein cholesterol

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

APOLIPOPROTEIN B; CORONARY HEART DISEASE; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; APOLIPOPROTEINS B; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; ENGLAND; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84884701053     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12129     Document Type: Article

References (29)

1. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
3. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III) final report. Circulation 2002;106:3143-421.
4. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14(Suppl. 2):S1-113.
5. Reiner Z, Tapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O. ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2011;32:1769-818.
6. Sazonov V, Beetsch J, Phatak H, Wentworth C, Evans M. Association between dyslipidemia and vascular events in patients treated with statins: report from the UK general practice research database. Atherosclerosis 2010;208:210-6.
7. Lim S, Park YM, Sakuma I, Koh KK. How to control residual cardiovascular risk despite statin treatment: focusing on HDLcholesterol. Int J Cardiol 2013;166:8-14.
8. The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993- 2000.
9. Ramjee V, Sperling LS, Jacobson TA. Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. J Am Coll Cardiol 2011;58:457-63.
10. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011;4:337-45.
11. Lavie CJ, Milani RV, O'Keefe JH. To B or not to B: is non-highdensity lipoprotein cholesterol an adequate surrogate for apolipoprotein B? Mayo Clin Proc 2010;85:446-50.
12. Robinson JG. Using apolipoprotein B to manage dyslipidemia. Mayo Clin Proc 2010;85:769.
13. Robinson JG. Are you targeting non-high-density lipoprotein cholesterol? J Am Coll Cardiol 2009;55:42-4.
14. Arsenault BJ, Rana JS, Stroes ESG, Despr_es JP, Shah PK, Kastelein JJP. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol 2009;55:35-41.
15. Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 1999;80:95-103.
16. Khaw KT, Wareham N, Bingham S, Welch A, Luben R, Day N. Combined impact of health behaviours and mortality in men and women: the EPIC-norfolk prospective population study. PLoS Med 2008;5:e12.
17. Albers JJ, Marcovina SM, Kennedy H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials. Clin Chem 1992;38:658-62.
18. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet 2008;366:1267-78.
19. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
20. van der Steeg WA, Boekholdt SM, Stein EA, El-Harchaoui K, Stroes ESG, Sandhu MS. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med 2007;146:640-8.
21. Parish S, Peto R, Palmer A, Clarke R, Lewington S, Offer A. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J 2009;30:2137-46.
22. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33.
23. McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008;372:224-33.
24. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.
25. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 2009;53:316-22.
26. Kastelein JJP, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008;117:3002-9.
27. Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, Hoefner DM. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC lipoproteins and vascular diseases division working group on best practices. Clin Chem 2009;55:407-19.
28. Rana JS, Boekholdt SM. Should we change our lipid management strategies to focus on non-high-density-lipoprotein cholesterol? Curr Opin Cardiol 2010;25:622-6.
29. Mora S, Rifai N, Buring JE, Ridker PM. Comparison of LDL cholesterol concentrations by friedewald calculation and direct measurement in relation to cardiovascular events in 27 331 women. Clin Chem 2009;55:888-94.